10-Q: Werewolf Therapeutics Reports Progress in Early-Stage Clinical Trials, Secures Additional Funding

Werewolf Therapeutics, a biopharmaceutical company developing novel cancer immunotherapies, announced progress in its Phase 1/1b clinical trials for WTX-124 and WTX-330, alongside a new $60 million loan agreement.

Summary

• Werewolf Therapeutics is developing conditionally activated immunotherapies for cancer treatment, leveraging its proprietary PREDATOR platform.
• The company's lead product candidates, WTX-124 and WTX-330, are in Phase 1/1b and Phase 1 clinical trials, respectively, for multiple tumor types.
• Preliminary data from the WTX-124 trial showed proof of mechanism and proof of concept, with ongoing dose escalation.
• Initial data from the WTX-330 trial was reported in June 2024.
• The company received FDA alignment on the comparability path for WTX-330 for an improved manufacturing process.
• Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule.
• In June 2024, Werewolf executed a transfer agreement to assign its rights in a development agreement with a contract manufacturer of JZP898 to Jazz, completing its material performance obligations under the collaboration agreement.
• The company reported a net loss of $17.2 million for the three months ended June 30, 2024, and an accumulated deficit of $377.5 million.
• Werewolf secured a $60 million loan agreement with K2 HealthVentures in May 2024 and repaid its previous $40 million loan with Pacific Western Bank.
• The company also raised $21.1 million in net proceeds through its at-the-market offering during the six months ended June 30, 2024.
• As of June 30, 2024, Werewolf had $135.3 million in cash and cash equivalents, which is expected to fund operations through at least the first quarter of 2026.

Sentiment

Score: 4

Explanation: The company is making progress in its clinical trials and has secured additional funding, but it continues to incur significant losses and faces substantial challenges in a highly competitive industry. The reliance on future capital raises and the uncertainty of clinical trial outcomes contribute to a cautious outlook.

Positives

• Progress is being made in the Phase 1/1b clinical trial for WTX-124, with preliminary data showing proof of mechanism and proof of concept.
• Initial data from the Phase 1 clinical trial for WTX-330 was reported in June 2024.
• The company received FDA alignment on the comparability path for WTX-330 for an improved manufacturing process.
• The collaboration with Jazz Pharmaceuticals provides potential for significant milestone payments and royalties.
• The new $60 million loan agreement with K2 HealthVentures provides additional funding for operations.
• The company successfully raised $21.1 million through its at-the-market offering.
• Cash and cash equivalents are estimated to fund operations through at least the first quarter of 2026.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• No products are approved for commercial sale, and the company has not generated any revenue from product sales.
• The company is early in its development efforts, and its product candidates require significant additional preclinical and clinical development.
• The company reported a net loss of $17.2 million for the three months ended June 30, 2024.
• The accumulated deficit as of June 30, 2024, was $377.5 million.
• Substantial additional funding will be needed to complete the development and commercialization of product candidates.

Risks

• The company's approach to drug discovery and development is unproven.
• Manufacturing INDUKINE molecules is complex and subject to risk.
• Clinical trials are expensive, time-consuming, and involve uncertain outcomes.
• The company may encounter substantial delays in clinical trials.
• Product candidates may cause undesirable side effects.
• The company faces substantial competition.
• The company relies on third parties to conduct preclinical studies and clinical trials.
• The company relies on third parties to manufacture its product candidates.
• The company's intellectual property protection may be inadequate.
• The company may be subject to costly and damaging liability claims.
• The company may not be able to obtain or maintain necessary regulatory approvals.
• The company may not be able to successfully commercialize its product candidates.
• Changes in tax laws or regulations could adversely affect the company.
• The company's ability to utilize net operating loss carryforwards may be limited.
• The company's loan agreement contains operating covenants that restrict its flexibility.
• Raising additional capital may cause dilution to stockholders or restrict operations.
• The company may be unable to obtain orphan drug designation or exclusivity.
• The company is subject to extensive healthcare laws and regulations.
• The company is subject to privacy and data security laws and regulations.
• The company is subject to export control, import, sanctions, anti-corruption, and anti-money laundering laws.
• The company may be adversely affected by unfavorable economic conditions.
• The company may engage in strategic transactions that could impact its liquidity and increase expenses.
• The company's stock price may be volatile.
• The company's principal stockholders and management own a significant percentage of the company's stock.
• The company has incurred and will continue to incur increased costs as a result of operating as a public company.
• The company has identified material weaknesses in its internal control over financial reporting in the past.

Future Outlook

Werewolf Therapeutics expects its existing cash and cash equivalents to be sufficient to fund its operational expenses and capital expenditure requirements through at least the first quarter of 2026. The company plans to continue advancing its clinical trials for WTX-124 and WTX-330, progress preclinical development of WTX-712 and WTX-518, and discover and develop additional product candidates.

Industry Context

Werewolf Therapeutics operates in the highly competitive field of cancer immunotherapy. The company's focus on conditionally activated INDUKINE molecules represents a novel approach to stimulating the immune system against tumors. The development of immunotherapies for cancer treatment is a rapidly evolving area, with many companies pursuing various modalities, including cytokines, monoclonal antibodies, cell therapies, oncolytic viruses, and vaccines.

Comparison to Industry Standards

• Werewolf's WTX-124, if approved, may face competition from other Interleukin-2 (IL-2) based cancer therapies, including Proleukin (aldesleukin) and modified IL-2 programs in development by companies such as Anaveon AG, Anwita Biosciences, Inc., Ascendis Pharma A/S, Asher Biotherapeutics, Inc., Aulos Bioscience, Inc., BioNTech SE, Cue Biopharma, Inc., DEKA Biosciences, Inc., Merck & Co., Inc., Medicenna Therapeutics Corp., Mural Oncology PLC, F. Hoffmann-La Roche AG, Synthekine, Inc., and Xilio Therapeutics, Inc.
• WTX-330, if approved, may face competition from other IL-12 cytokine programs in clinical and preclinical development for oncology indications, including programs from Sanofi S.A. (Amunix), DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), Turnstone Biologics Corp. (partnered with Takeda Pharmaceutical Company Limited), Philogen S.p.A., OncoSec Medical Incorporated, Sonnet BioTherapeutics, Inc., Xilio Therapeutics, Inc. and Zymeworks Inc.

Related Party Transactions

• In May 2022, the company entered into a sublease agreement with Crossbow Therapeutics, Inc., for which entities affiliated with MPM Capital are also beneficial owners. The sublease ended in March 2024.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises and the conversion feature of the K2HV Loan Agreement. Stock price may be volatile due to the early stage of development and the risks associated with clinical trials and regulatory approvals.
• Employees: The company's ability to retain key employees and attract qualified personnel will be crucial for its success. Growth may create new opportunities but also challenges in managing expansion.
• Customers: If the company's product candidates are successfully developed and approved, they could offer new treatment options for patients with cancer.
• Suppliers: The company relies on third-party manufacturers and suppliers, and any disruptions in these relationships could impact development timelines and costs.
• Creditors: The K2HV Loan Agreement includes covenants that restrict the company's operational and financial flexibility. The company's ability to repay its debt will depend on its future financial performance and ability to raise additional capital.

Next Steps

• Continue dose escalation and expansion in the Phase 1/1b clinical trial for WTX-124 as a monotherapy and in combination with pembrolizumab.
• Continue dose escalation and expansion in the Phase 1 clinical trial for WTX-330.
• Integrate the improved manufacturing process for WTX-330 into the clinical development program.
• Further the development of preclinical product candidates WTX-518 and WTX-712.
• Continue to discover and develop additional product candidates.
• Potentially draw down additional tranches under the K2HV Loan Agreement, subject to meeting certain milestones and conditions.

Key Dates

Keywords

Werewolf Therapeutics, cancer immunotherapy, INDUKINE molecules, PREDATOR platform, WTX-124, WTX-330, JZP898, clinical trials, biopharmaceutical, oncology, Interleukin-2, Interleukin-12, Interferon alpha, Jazz Pharmaceuticals, K2 HealthVentures, loan agreement, at-the-market offering